1. Academic Validation
  2. MiR-155 is involved in major depression disorder and antidepressant treatment via targeting SIRT1

MiR-155 is involved in major depression disorder and antidepressant treatment via targeting SIRT1

  • Biosci Rep. 2018 Dec 21;38(6):BSR20181139. doi: 10.1042/BSR20181139.
Xun Wang 1 Bing Wang 2 Jianping Zhao 1 Caixing Liu 3 Xianpeng Qu 4 Yuhuan Li 1
Affiliations

Affiliations

  • 1 Department of Psychology, Qingdao Mental Health Center, Qingdao City, Shandong Province 266000, P.R. China.
  • 2 Department of Pharmacy, Qingdao Women and Children's Hospital, Qingdao City, Shandong Province 266000, P.R. China.
  • 3 Department of Psychology, Qingdao Mental Health Center, Qingdao City, Shandong Province 266000, P.R. China qzpckb2@163.com.
  • 4 Department of Internal Medicine, Qingdao Eighth People's Hospital, Qingdao City, Shandong Province 266000, P.R. China.
Abstract

Major depressive disorder (MDD) is a common mood disorder, and the treatment of MDD requires a variety of biopsychosocial approaches. The role of Silent information regulator 1 (SIRT1) in the regulation of MDD has recently been implicated. Here, we aimed to explore and elucidate the therapeutic effects of a MicroRNA, miR-155, in the treatment of MDD. With quantitative Real-Time PCR (qRT-PCR) analysis, we confirmed that cellular and serum levels of miR-155 were up-regulated in individuals with depression compared with those in healthy controls. TargetScan analysis indicated that SIRT1 is a target of miR-155, which was confirmed by dual-luciferase assay, qRT-PCR and Western blot analyses. Treatment of human neural progenitor cells with the antidepressant drug citalopram down-regulated miR-155 expression and up-regulated SIRT1 expression. These results suggest that miR-155 is an important factor in the pathophysiology of depression. miR-155 is a potential target for the development of new antidepressant treatments.

Keywords

SIRT1; antidepressant treatments; depression; miR-155.

Figures
Products